Feasibility and Efficacy of Cold Plasma for Direct Deposition of Topotecan

Le résumé fourni par la source

Cold plasma therapy is emerging as an innovative modality, with the potential to exhibit synergistic effects when combined with chemotherapeutic agents. A new plasma-assisted local delivery of oncology drugs was developed to mediate the drug delivery and possibly enhance the drug uptake and chemotherapeutical action. Topotecan (TPT) was selected as the candidate drug because despite the potent antitumor activity, the systemic administration is limited. The influence of the plasma deposition process on the characteristics of TPT, was investigated to determine potential structure and activity changes. Fluorescence analysis showed that the emission spectrum of TPT is altered by modifications to the A-ring, influenced by solvent polarity, pH, and moisture content, while deposition parameters and surface characteristics also played important roles, but no structural changes to the A-ring were indicated with plasma exposure. A TPT solution was sprayed into a non-thermal plasma and deposited onto polystyrene microplates. Results showed that the TPT elution from the microplates into cell culture medium was almost complete and instantaneous. Initial findings with U251-mg glioblastoma cell line model suggest that plasma deposition enhances drug stability without compromising biological activity compared to a wet deposition of TPT. This result was confirmed using High Performance Liquid Chromatography. These results reveal a new mode of delivery for effective topotecan therapeutic use and can open the doors to new combinations for local drug application.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.